Literature DB >> 32020293

The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Dragana Stanic-Vucinic1, Stefan Nikolic2, Katarina Vlajic1, Mirjana Radomirovic1, Jelena Mihailovic1, Tanja Cirkovic Velickovic1,3,4,5, Sanja Grguric-Sipka6.   

Abstract

The reactions of four cymene-capped ruthenium(II) compounds with pro-apoptotic protein, cytochrome c (Cyt), and anti-proliferative protein lysozyme (Ly) in carbonate buffer were investigated by ESI-MS, UV-vis absorption, and CD spectroscopy. The complexes with two chloride ligands (C2 and C3) were more reactive toward proteins than those with only one (C1 and C4), and the complex with S,N-chelating ligand (C4) was less reactive than one with O,N-chelating ligand (C1). Dehalogenated complexes are most likely species, initially coordinating proteins for all tested complexes. During the time, protein adducts vividly exchanged non-arene organic ligand L with CO32- and OH-, while cymene moiety was retained. In water, only dehalogenated adducts were identified suggesting that in vivo, in the presence of various anions, dynamic ligand exchange could generate different intermediate protein species. Although all complexes reduced Cyt, the reduction was not dependent on their reactivity to protein, implying that initially noncovalent binding to Cyt occurs, causing its reduction, followed by coordination to protein. Cyt reduction was accompanied with rupture of ferro-Met 80 and occupation of this hem coordination site by a histidine His-33/26. Therefore, in Cyt with C2 and C3, less intensive reduction of hem iron leaves more unoccupied target residues for Ru coordination, leading to more efficient formation of covalent adducts, in comparison to C1 and C4. This study contributes to development of new protein-targeted Ru(II) cymene complexes, and to the design of new cancer therapies based on targeted delivery of Ru(II) arene complexes bound on pro-apoptotic/anti-proliferative proteins as vehicles.

Entities:  

Keywords:  Anticancer metallodrugs; Mass spectrometry; Protein metalation; Ruthenium(II)-cymene complexes

Mesh:

Substances:

Year:  2020        PMID: 32020293     DOI: 10.1007/s00775-020-01758-3

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  50 in total

1.  Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy.

Authors:  Santimukul Santra; Charalambos Kaittanis; J Manuel Perez
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.

Authors:  Haimei Chen; John A Parkinson; Simon Parsons; Robert A Coxall; Robert O Gould; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2002-03-27       Impact factor: 15.419

3.  Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies.

Authors:  L Messori; A Merlino
Journal:  Chem Commun (Camb)       Date:  2017-10-24       Impact factor: 6.222

4.  Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide.

Authors:  Fuyi Wang; Juraj Bella; John A Parkinson; Peter J Sadler
Journal:  J Biol Inorg Chem       Date:  2005-02-26       Impact factor: 3.358

5.  Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.

Authors:  Claudine Scolaro; Adrian B Chaplin; Christian G Hartinger; Alberta Bergamo; Moreno Cocchietto; Bernhard K Keppler; Gianni Sava; Paul J Dyson
Journal:  Dalton Trans       Date:  2007-09-26       Impact factor: 4.390

6.  Delivery of chemically glycosylated cytochrome c immobilized in mesoporous silica nanoparticles induces apoptosis in HeLa cancer cells.

Authors:  Jessica Méndez; Moraima Morales Cruz; Yamixa Delgado; Cindy M Figueroa; Elsie A Orellano; Myraida Morales; Alina Monteagudo; Kai Griebenow
Journal:  Mol Pharm       Date:  2013-12-10       Impact factor: 4.939

7.  Preparation and characterization of a pentaammineruthenium(III) derivative of horse heart ferricytochrome c.

Authors:  K M Yocom; J B Shelton; J R Shelton; W A Schroeder; G Worosila; S S Isied; E Bordignon; H B Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

Authors:  F Piccioli; S Sabatini; L Messori; P Orioli; Ch G Hartinger; B K Keppler
Journal:  J Inorg Biochem       Date:  2004-06       Impact factor: 4.155

9.  Interaction of an anticancer ruthenium complex HInd[RuInd2Cl4] with cytochrome c.

Authors:  Lilianna Trynda-Lemiesz
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

10.  Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.

Authors:  Angela Casini; Guido Mastrobuoni; Mattia Terenghi; Chiara Gabbiani; Enrico Monzani; Gloriano Moneti; Luigi Casella; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2007-08-07       Impact factor: 3.358

View more
  1 in total

1.  Modulation of Diverse Procoagulant Venom Activities by Combinations of Platinoid Compounds.

Authors:  Vance G Nielsen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.